Arteris

Arteris reported results (Aug 06, 2026). EPS came in at -$0.10 against a -$0.04 consensus, missed by 140.4%. Revenue was $24.1M versus $23.5M expected, beat by 2.8%.

Arteris reported a strong Q1 FY2026, with both revenue and EPS beating street estimates. The company raised its full-year guidance, reflecting continued momentum in its business.

Arteris beat Q4 consensus on revenue by +8.6% and EPS by +37.5%, but the more actionable point is that management guided to an ACV-plus-royalties exit rate of $100 million to $104 million for 2026 after ending Q4 at $83.6 million. The market was likely priced for another narrow loss-reduction print; what it got was evidence that the contracted backlog and Cycuity contribution can pull the model toward scale faster than the headline GAAP loss suggests.

Arteris sold off the wrong line item if investors treated the $17.4 million revenue miss as the story: the quarter’s variant signal is that ACV plus royalties and RPO both cleared management’s targets while losses and cash flow moved in the right direction. The market was priced for cleaner near-term revenue, but the surprise worth underwriting is a larger forward revenue base, not a one-quarter timing gap.

Arteris did not beat the quarter in a way that should move a model: revenue surprised by only +0.9% and EPS was exactly in line. The variant view is that investors focused on the flat sequential revenue and unchanged loss are missing the more investable point, which is that ACV plus royalties and RPO are pulling away from current revenue while gross margin has stayed near 90%, making the next debate about conversion timing rather than demand.